387 related articles for article (PubMed ID: 12776143)
1. Public biotechnology 2002--the numbers.
Lähteenmäki R; DeFrancesco L
Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
[No Abstract] [Full Text] [Related]
2. Public biotech 2006 - the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
[No Abstract] [Full Text] [Related]
3. Public biotechnology 2003-the numbers.
Lähteenmäki R; Baker M
Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
[No Abstract] [Full Text] [Related]
4. Public biotechnology 2001--the numbers.
Lähteenmäki R; Fletcher L
Nat Biotechnol; 2002 Jun; 20(6):551-5. PubMed ID: 12042853
[No Abstract] [Full Text] [Related]
5. Public biotechnology 2005--the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
[TBL] [Abstract][Full Text] [Related]
6. Private biotech 2004--the numbers.
Hodgson J
Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
[TBL] [Abstract][Full Text] [Related]
7. State of biotech sector--2005.
Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):603. PubMed ID: 16763577
[No Abstract] [Full Text] [Related]
8. Public biotech 99: the numbers.
Lähteenmäki R; Hodgson J
Nat Biotechnol; 2000 May; 18(5):499-503. PubMed ID: 10802615
[No Abstract] [Full Text] [Related]
9. Public biotech 2010--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
[No Abstract] [Full Text] [Related]
10. Enthusiasm cools in Q2.
Lawrence S
Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352
[No Abstract] [Full Text] [Related]
11. The biotechnology industry: What's next?
Guertin PA
Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
[No Abstract] [Full Text] [Related]
12. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
13. Wrong numbers?
Nat Biotechnol; 2010 Aug; 28(8):761. PubMed ID: 20697382
[No Abstract] [Full Text] [Related]
14. Sunbaked biotechnology in Australia.
Littlejohn T
Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
[No Abstract] [Full Text] [Related]
15. The industry in Europe: more together than apart.
Med Device Technol; 2005 Nov; 16(9):32, 34, 36-7. PubMed ID: 16438447
[TBL] [Abstract][Full Text] [Related]
16. Public markets show signs of life.
Mitchell P
Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
[No Abstract] [Full Text] [Related]
17. Fortune 500 largest U.S. corporations.
Fortune; 1997 Apr; 135(8):F1-23. PubMed ID: 10166665
[No Abstract] [Full Text] [Related]
18. Public biotech 2007--the numbers.
Lawrence S; Lähteenmäki R
Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
[TBL] [Abstract][Full Text] [Related]
19. 2007--a banner year for biotech.
Lawrence S
Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
[No Abstract] [Full Text] [Related]
20. Lack of private financing hobbles emerging biotech regions.
Jia H; Jayarama KS; Astvatsaturyan M
Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
